



LEI: 549300Q7EXQQH6KF7Z84

16 May 2025

RTW Biotech Opportunities Ltd
(the "Company")

Notice of Annual General Meeting

RTW Biotech Opportunities Ltd announces that its Annual General Meeting (**AGM**) will be held at 1st Floor Royal Chambers, St Julian's Avenue St Peter Port, Guernsey on 9 June 2025 at 2pm BST. The Notice of AGM was dispatched to all shareholders on 15 May 2025.

A copy of the Notice of AGM has been submitted to the National Storage Mechanism and will shortly be available for inspection at <https://data.fca.org.uk/#/nsm/nationalstoragemechanism>. The Notice of AGM may also be viewed on the Company's website at www.rtwfunds.com/rtw-biotech-opportunities-ltd.

The Annual Report and Audited Financial Statements for the year ended 31 December 2024 (the **Annual Report**) is also available on the Company's website at www.rtwfunds.com/rtw-biotech-opportunities-ltd.

You will not have received a hard copy proxy form for the AGM in the post. You can instead submit your proxy vote electronically via the Investor Centre app or by accessing the web browser at <https://uk.investorcentre.mpms.mufg.com/>. Full details of how to vote are set out in the Notes to the Notice of Meeting. Please submit your proxy vote so as to reach the Company's registrar as soon as possible and in any event no later than 2pm BST on 5 June 2025 or, if you are a CREST member, by using the service provided by Euroclear. **Shares held on your behalf by a broker or nominee must be voted by the broker, per your instructions, and cannot be voted at <https://uk.investorcentre.mpms.mufg.com/>.** The completion of the form of proxy will not preclude a member from attending and voting in person at the meeting if it is so allowed.

If any shareholder has questions related to the business of the AGM, please submit your queries to biotechopportunities@rtwfunds.com by 2pm BST on 5 June 2025.

Enquiries:

RTW Investments, LP - Investment Manager	+44 (0)20 7959 6361
Woody Stileman (Business Development)	biotechopportunities@rtwfunds.com
Oliver Kenyon (Business & Corporate Development)	
Krishna McCune (Investor Relations)	
Cadarn Capital - PR & IR Partner	
Lucy Clark (PR)	+44 (0)7984 184 461 / lucy@cadarncapital.com
David Harris (Distribution)	+44 (0)7368 883 211 / david@cadarncapital.com
Deutsche Numis - Joint Corporate Broker	+44 (0)20 7260 1000
Freddie Barnfield	
Nathan Brown	
Euan Brown	
BofA Securities - Joint Corporate Broker	+44 (0)20 7628 1000
Edward Peel	
Alex Penney	
Altum (Guernsey) Limited	+44 (0)1481 703 100
Joanna Duquemin Nicolle	
Sadie Morrison	

About RTW Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd for more information.

The information in this announcement may include forward-looking statements, which are based on the current expectations and projections about future events, and in certain cases can be identified by the use of terms such as "may", "will", "should", "expect", "anticipate", "project", "estimate", "intend", "continue", "target", "believe" (or the negatives thereon) or other variations thereon or comparable terminology. These forward-looking statements, as well as those included in any related materials, are subject to risks, uncertainties and assumptions about the Company and/or its underlying investments, including, among other things, the development of the applicable entity's business, trends in its operating industry, expected use of financing proceeds and future capital expenditures and acquisitions. In light of these risks, uncertainties and assumptions, the events in the forward-looking statements may not occur.

The information contained in this announcement is given at the date of its publication (unless otherwise marked). No reliance may be placed for any purpose whatsoever on the information or opinions contained in this announcement or on its completeness, accuracy or fairness.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NOAEASSSFLSEFA